Mitochon Pharmaceuticals 2,4 DNP Cancer Treatment Patent Application
Summary
Mitochon Pharmaceuticals, Inc. has filed patent application US20260108476A1 covering compositions and methods for treating cancer using 2,4-DNP (dinitrophenol) and prodrugs thereof. The application, originally filed on August 4, 2022 (Application No. 18681016), was published on April 23, 2026. Named inventors include John Gerard Geisler, Robert Alonso, and Marcelo G. Bonini. The CPC classifications indicate therapeutic applications across multiple drug compound categories (A61K 31/06 through A61P 35/00).
“Compositions and methods of treatment of cancer including DNP and/or prodrugs of DNP are disclosed.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
Mitochon Pharmaceuticals, Inc. has published a patent application (US20260108476A1) for compositions and methods of treating cancer using 2,4-DNP (dinitrophenol) and its prodrugs. The application covers therapeutic formulations and treatment protocols. Inventors John Gerard Geisler, Robert Alonso, and Marcelo G. Bonini are named. The patent application was filed August 4, 2022 and published April 23, 2026.
Pharmaceutical and biotechnology companies developing mitochondrial-targeted cancer therapies, metabolic oncology programs, or DNP-related compounds should review this filing to assess potential freedom-to-operate implications. The broad CPC classifications spanning multiple A61K compound categories suggest the patent may have claims covering various derivative formulations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
2,4 DNP and Prodrugs Thereof for Treatment of Cancer
Application US20260108476A1 Kind: A1 Apr 23, 2026
Assignee
Mitochon Pharmaceuticals, Inc.
Inventors
John Gerard GEISLER, Robert ALONSO, Marcelo G. BONINI
Abstract
Compositions and methods of treatment of cancer including DNP and/or prodrugs of DNP are disclosed.
CPC Classifications
A61K 31/06 A61K 31/203 A61K 31/255 A61K 31/337 A61K 31/4196 A61K 31/4453 A61K 31/495 A61K 31/519 A61K 31/53 A61K 31/5375 A61K 31/565 A61K 31/69 A61K 31/704 A61K 31/706 A61P 35/00
Filing Date
2022-08-04
Application No.
18681016
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.